Clinical Trial Update: Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating padsevonil as adjunctive therapy for drug-resistant focal-onset seizures was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-resistant Epilepsy
• Focal Onset Seizures

Drugs mentioned

• Padsevonil (padsevonil)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Drug-Resistant Epilepsy, Focal-Onset Seizures | Phase 2 | Status: TERMINATED | Results posted: 2021-12-29